ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in…
News
ProMIS Neurosciences Announces First Quarter 2023 Financial Results and Recent Highlights
Received FDA clearance for investigational new drug (IND) application for lead therapeutic candidate, PMN310, in…
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data…
Bellerophon Provides Clinical Program Update and Reports First Quarter 2023 Financial Results
Last Patient Completed Blinded Treatment in REBUILD Phase 3 Trial for INOpulse®; Pivotal Top-line Data…
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN…
Adamis Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
Management to host webcast/conference call today at 2:00 p.m. PT / 5:00 p.m. ET SAN…
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants,…
Vaccinex Reports First Quarter 2023 Financial Results and Provides Corporate Update
Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants,…
ERYTECH Provides Update on the Announced Combination with PHERECYDES
ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement…
ERYTECH Provides Update on the Announced Combination with PHERECYDES
ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement…
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”)…
Windtree Therapeutics Reports First Quarter 2023 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., May 15, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or “the Company”)…
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for…
Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update
Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for…
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…
Checkpoint Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Highlights
FDA accepted for filing the Biologics License Application for cosibelimab in patients with metastatic or…
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
OpGen Reports First Quarter 2023 Financial Results and Provides Business Update
Total revenue for the first quarter of 2023 was approximately $0.91 million, an increase of…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…
Sanara MedTech Inc. Announces First Quarter 2023 Results
FORT WORTH, TX, May 15, 2023 (GLOBE NEWSWIRE) — Sanara MedTech Inc. Based in Fort…